ALDX - Aldeyra Therapeutics Inc.

-

$undefined

N/A

(N/A)

Aldeyra Therapeutics Inc. NasdaqCM:ALDX Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Location: 131 Hartwell Avenue, Lexington, MA, 02421, United States | Website: https://www.aldeyra.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

62.07M

Cash

90.06M

Avg Qtr Burn

-11.43M

Short % of Float

9.97%

Insider Ownership

3.13%

Institutional Own.

56.36%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

NDA

Resubmission

Reproxalap (ADX-102) Details
Rare genetic disease, Rare diseases, Allergic conjunctivitis

Phase 3

Update

ADX-2191 Details
Eye disease , Retinitis Pigmentosa

Phase 2/3

Initiation

ADX-629 Details
Alcoholic hepatitis, Liver disease

Big Mover™

Susp. Mover™

Phase 2

Data readout

ADX-629 Details
Sjögren-Larsson Syndrome

Phase 2

Data readout

ADX-629 Details
Atopic dermatitis

Phase 2a

Update

ADX-246 Details
Atopic dermatitis, Skin disease/disorder

Phase 1/2

Data readout

ADX-248 Details
Age-related macular degeneration, Geographic atrophy

Phase 1/2

Initiation

ADX-248 Details
Atopic dermatitis, Skin disease/disorder

Phase 1

Initiation

ADX-743 Details
Metabolic disorder, Obesity

IND

Submission

ADX-631 Details
Eye disease , Geographic atrophy

IND

Submission

ADX-629 Details
Idiopathic Nephrotic Syndrome

Failed

Discontinued

ADX-629 Details
Chronic cough

Failed

Discontinued

ADX-2191 Details
Eye disease , Proliferative vitreoretinopathy, Rare diseases, Primary Vitreoretinal Lymphoma

Failed

Discontinued